Form 4: Enliven Therapeutics CEO Sells 12,500 Shares

Enliven Therapeutics' President and CEO, Samuel Kintz, sold 12,500 shares of common stock for a weighted average price of $21.8191 per share.

Summary

• Samuel Kintz, President and CEO, and Director of Enliven Therapeutics, Inc. (ELVN), reported a sale of common stock.
• On November 17, 2025, Kintz disposed of 12,500 shares of ELVN common stock.
• The shares were sold at a weighted average price of $21.8191 per share, with individual trades ranging from $21.37 to $22.3537.
• This transaction was executed under a Rule 10b5-1 trading plan adopted on November 15, 2024.
• Following the transaction, Kintz beneficially owns 890,392 shares indirectly through The Kintz & Egan Trust Dated March 30, 2019.

Sentiment

Score: 5

Explanation: Neutral. The sale is a pre-planned transaction under a 10b5-1 plan, which typically indicates a non-discretionary sale rather than a reaction to new information. While insider selling can sometimes be viewed negatively, the pre-planned nature mitigates immediate concerns.

Positives

• The sale was conducted pursuant to a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled, non-discretionary transaction rather than a reaction to new information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market as it reduces insider ownership.

Risks

• No specific risks are detailed in this Form 4 filing beyond the general market perception of insider selling.

Future Outlook

N/A

Industry Context

N/A

Related Party Transactions

• The shares beneficially owned by the reporting person are held of record by The Kintz & Egan Trust Dated March 30, 2019, for which the reporting person serves as trustee.

Stakeholder Impact

• Shareholders may perceive a slight negative sentiment due to insider selling, though mitigated by the 10b5-1 plan.
• Employees and other stakeholders are unlikely to be directly impacted by this specific transaction.

Key Dates

Recommendation

The sale by President and CEO Samuel Kintz was conducted under a pre-arranged Rule 10b5-1 trading plan, adopted a year prior to the transaction date. This indicates a scheduled, non-discretionary sale rather than a reaction to new material information. While insider selling can sometimes be a bearish signal, the pre-planned nature suggests it's part of personal financial management rather than a reflection of the company's immediate prospects. Therefore, the filing itself does not provide a strong basis for a change in investment thesis, warranting a 'hold' recommendation.

Keywords

Enliven Therapeutics, ELVN, Samuel Kintz, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Director